Recently, EBV LMP1-specific DNAzyme, DZ1, inhibits the majority of oncogenic signaling pathways converging on sets of transcription factors that ultimately control gene expression patterns resulting in tumor formation, progression, and metastasis.[19] Our data showed that DZ1 can inhibit EBV LMP1-induced promoter activity of cyclin D1 via EGFR or STAT3 and that DZ1 enhanced cyclin D1 promoter inhibition based on experiments with mutants of EGFR or STAT3. Here, CCND1 is linked to neoplasm.